RAPT THERAPEUTICS, INC. (RAPT) News
Filter RAPT News Items
RAPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RAPT News From Around the Web
Below are the latest news stories about RAPT THERAPEUTICS INC that investors may wish to consider to help them evaluate RAPT as an investment opportunity.
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyPositive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeksFurther deepening of response in percent change in EASI, EASI-50 and vIGA observed two weeks after end of treatmentSignificant changes in transcriptional profile of patients treated with zelnecirnon at Day 29, which were also significantly correlated with improvements in clinical efficacy measuresZelnecirnon |
RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical TrialsNet Loss Widens in Q3 2023; Strong Cash Position to Support Operations Through Mid-2025 |
RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsCompany maintains strong cash position of $184.8 millionSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and the nine months ended September 30, 2023. “We continue to ma |
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR of 50% in patients with PD-L1 high expression (TPS ≥50%) and 38% in patients with PD-L1 low expression (TPS 1-49%) - RAPT to host webcast conference call today at 10:00 am PT SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- RAPT |
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in NovemberSOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November: Guggenheim Healthcare Talks: 5th Annual I&I Confer |
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingSOUTH SAN FRANCISCO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present two posters on FLX475, its oncology drug candidate, at the Society for Immunotherapy of Cancer 2023 Annual Meeting taking place November 3-5, 2 |
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your PortfolioDive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. |
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in SeptemberSOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in September: Wells Fargo 2023 Healthcare Conference – Fireside |
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48%The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |